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Abstract
Momordica charantia L. is growing in many tropical and subtropical regions; the
fruits of bitter melon are also gradually becoming popular for treating diabetes and
associated diseases. Over 248 compounds belonging to the lipids, phenolics and
terpenoids class are reported by diverse studies. However, M. charantia L. appears to
be an inimitable species that synthesizes a diverse range of natural products in the
fruits, leaves, stems and roots. The cucurbitane types of triterpenes exist in the
various tissues of the plant in their aglycone as well as glycosylated forms. The bitter
melon seems to exert their lipid lowering and antiobesity effects via several mecha-
nisms like PPARs, LXRs, SREBPs, and Sirts mediated fat metabolism in various
tissues, prevent adipocyte hypertrophy and visceral fat accumulation.M. charantia L.
has been comprehensively studied worldwide for its therapeutic properties to treat a
number of diseases like diabetes, dyslipidaemia, obesity, and certain cancers. This
chapter apparently displays an encompassing literature review on vast potential of
bitter melon as antiobesity agent and assembles data on complex phytochemistry.
Keywords: obesity, phytochemicals, bitter melon, cucurbitane type terpenoids
1. Introduction
Momordica charantia L. or Bitter Melon, also known as balsam pear or Karela, is
a vegetable and common food in Indian cuisine and has been used comprehensively
in folk medicine. Momordica charantia L. is tropical or subtropical creeping belong-
ing to family Cucurbitaceae and widely used as medicinal herb from ancient time
(Figure 1). The Latin name Momordica means “to bite” referring to the serrated
edges of the leaf, which appear as if they have been bitten. The major regions of M.
charantia L. cultivation are Asia including China, India, Sri Lanka and Thailand,
central and South America and North America [1]. In Ayurveda, the fruit is con-
sidered as tonic, stomachic, stimulant, emetic, antibilous, laxative and alterative.
Bitter melon has been used in various Asian traditional medicine systems for a long
time. It is well recognized, the plant is extensively in use in the Chinese, Indian
Ayurvedic, and Indonesian systems of medicines as well as in Japan [2].
The therapeutic significance of the plant is symbolized by the fruits which
contain about half a dozen seeds per gram of the fresh fruit. As the name implies,
the fruits are bitter and bitterness enhance with the level of maturity and hence
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earlier harvesting required to battle bitter taste. The leaves and young shoots of
bitter melon recognized to be used in traditional medicine as an herbal tea. The
range of pharmacological activities reported for bitter melon is rapidly increasing in
recent years and its claimed uses and potential applications for cancer and other
diseases have been extensively reviewed. Likewise, the range of medicinal claims
range from diabetes, hypertension, obesity, cancer, as well as AIDS. M. charantia L.
possesses various beneficial effects, including anti-cancer, anti-viral, antioxidant,
antiulcer, anti-obesity, anti-HIV, cytotoxic, anti-inflammatory, reduction of cho-
lesterol, inhibition of protein tyrosine phosphatase 1B, and anti-osteoporosis [3].
This chapter aims to highlight the complex phytochemistry and extensive review on
antiobesity potential of bitter melon with possible targets.
2. Plant profile
2.1 Botanical description
Cucurbitaceae family is known to comprise some 101 accepted genera and the
genus Momordica L. itself comprises of some 50 accepted species within the family
[4]. M. charantia L. was known previously by several synonyms including the
Cucumis argyi H. Lev., Cucumis intermedius M. Roem., Momordica anthelmintica
Schumach. & Thonn., Momordica charantia subsp. abbreviata (Ser.) Greb.,
Momordica charantia var. abbreviata Ser., Momordica charantia f. muricata
(Willd.)., Momordica charantia var. muricata (Willd.) Chakrav., Momordica
charantia var. pseudobalsamina Griseb., Momordica charantia var. zeylanica Hitchc.,
Momordica elegans Salisb., Momordica indica L., Momordica jagorana K.Koch.,
Momordica muricata Willd., Momordica papillosa Peckolt ex Rosenthal., Momordica
roxburghiana G. Don., Momordica senegalensis Lam., Momordica thollonii Cogn.,
Momordica zeylanica Mill. The botanical description of different parts of the plant
demonstrated in Table 1. The taxonomic hierarchy of bitter melon within the plant










The image describes plant parts of M. charantia L. unripe fruit; ripe fruit and seeds of plant.
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Family: Cucurbitaceae
Genus: Momordica Linn.
Species: Momordica charantia L.-balsampear
2.2 Phytochemistry
The main constituents of bitter melon are triterpenoids, saponins, protein, poly-
saccharides, steroid, alkaloid, lipid, and phenolic compounds. Several bioactive com-
pounds ofM. charantia L. have been recorded and the literature shown that these
were responsible for various pharmacological effects as depicted in Table 2 [5].
2.2.1 Triterpenoids
The most abundant phytochemical components of bitter melon fruits are the




Leaves Broadly ovate to orbicular in outline, cordate, narrowly decurrent on to petiole, sparsely
pubescent to densely villous on veins beneath, deeply palmately 3–7-lobed, lobes variously
sinuate-dentate or lobulate. Leaf lamina 10  12.5 cm.
Flowers Flowers are monoecious and solitary.
Male flowers: peduncle 0.3–5 cm long; bract 2–17 mm long, broadly ovate or reniform,
sessile, cordate, amplexicaul, pedicel 2–9.5 cm long. Receptacle-tube 1–5 mm long; lobes 3–
7 mm long, ovate-lanceolate. Petals 1.0–2.5 cm long, pale to deep yellow, ovate to obovate.
Female flowers: peduncle 0.2–5 cm long; bract 1–12 mm long; pedicel 1–10 cm long; ovary
8–11  2–4 mm, ovoid-rostrate to fusi-form, ridged, pilose on ridges, tuberculate;
receptacle-tube 1–3 mm long, lobes 2–5 mm long, lanceolate; petals 0.7–1.2 cm long.
Fruits Fruit 2.5–4.8  1.5–2.3 cm, ovoid-rostrate or ellipsoid, longitudinally ribbed and
tuberculate, bright orange-red, dehiscent into 3 valves; fruit-stalk 3.4–15 cm long.
Seeds Seeds 8–11, 4.5–8  2–3.5 mm, enveloped in sticky red pulp, ovate-elliptic to oblong in
outline; faces flattened, sculptured, with sinuate edges; margins grooved.
Petiole Petiole 0.5–7 cm long.
Table 1.




1 Triterpenoids Leaves, stem,
fruits




Seed Antiviral, anti-tumor, immune suppressant,
antimicrobial
3 Phenolics Fruit and seed Antioxidant, anti-inflammatory, immunostimulant
4 Saponin Fruit, root, seed Antihyperglycemic, hypolipidemic, antiviral,
bacteriostatic
5 Polysaccharide All parts of plant Antioxidant, antidiabetic, immune enhancement,
neuroprotective, antitumor
6 Lipid Seed Anti-tumor, antioxidant
7 Steroids Fruit and pericarp Antimicrobial
Table 2.
Bioactive components of Momordica charantia Linn. And their pharmacological effects.
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and toxicity. These were divided in two types primarily the cucurbitane-type and to
a less extent oleane type which may occur either in their glycosylated or aglycone
forms. The sugar monomers as β-D-glucopyranosyl, β-D-allopyranosyl, β-D-
xylopyranosyl occur in cucurbitane-type triterpenes either by their own as O-linked
glycosides, or in different combinations as disaccharides or polysaccharides. The
rare glycoside in these compounds was the 3-keto-glucoside [6]. An extremely large
and certainly exhibited 193 number of cucurbitane-type triterpenes isolated from
bitter melon having various pharmacological effects (Table 3) [7]. The fruits are
predominance source of terpenoids with great deal of structural diversity but the
leaves, stems and roots have also been shown to be good sources of these com-
pounds [8].
Momordicosides A and B were isolated firstly from the seeds of bitter melon
fruits; While, Momordicosides C, D and E were isolated as minor components of the
seeds [9]. The study on the fruits of M. charantia L. further added a
Momordicosides F1, F2, G, I, K and L as novel compounds in previous one [10].
The Momordicosides I and Momordicosides M along with other compounds have
also been isolated from the fruits of bitter melon [11]. Further additions of
Momordicosides M-O as a new compound were confirmed by chemical examina-
tion of the fresh fruits [12]. The Vietnamese origin dried fruits of M. charantia
had shown existence of an auxiliary three pioneering Momordicosides U, V and W.
The cucurbitane-type triterpenes which are known to be responsible for the
bitterness of the leaves and vines of the M. charantia L. are Momordicines.
The Momordicine IV and the malonyl derivative of Momordicine II,
Momordicine V was readily available in the leaves of bitter melon. The isolation of
Momordicines VI, VII, and VIII were first confirmed from the stems and leaves of
bitter melon [13].
The Goyaglycosides-a, b, c, d, e, f, g, and -h were isolated from the
fresh fruits of JapaneseM. charantia L. A novel compound Goyaglycoside I was an
additional triterpene isolated from the immature fruit of bitter melon [14]. The novel
Cucurbitane-type triterpene called karavilagenins A-C and five new triterpene gly-
cosides called karavilosides I-V were isolated from the dried fruit of M. charantia L.
[15]. The three novel compounds that they names charantosides A, B and C were
obtained from fruits of bitter melon. The methanol extracts of the fruits of Japanese
M. charantia L. shown charantosides I, II, III-VI, VII and VIII, however charantoside
IX and X were other novel compounds reported by the studies [16].
Another group of interesting triterpenoids are those known by their trivial
names kuguacins. Kuguacins A-E and Kuguacins F-S were isolated from the roots
and the leaves of bitter melon plant respectively [17]. Kuguacins II-VI was novel
compounds isolated together with various other known compounds from the fruit
of M. charantia L. From the aqueous ethanolic extracts of fresh fruits isolated eight
novel cucurbitane-type glycosides that they named kuguasaponins A-H. The
ethanolic extract of fruits of M. charantia L. identified 15 cucurbitane-type
triterpene glycosides including 4 new compounds, kuguaosides A-D [18].
2.2.2 Flavonoids and phenolic compounds
A number of phenolic compounds with many biological activities have been
isolated from bitter melon including, coumaric, caffeic, and ferulic acids as well as
the caffeic acid ester, chlorogenic acid, Benzoic, gallic and gentisic acid. The major
flavonoids and phenolic acids in the dried leaves of bitter melon were also analyzed
and found to be rutin, gentisic acid and coumaric acid [19]. While the phenolic
acids and flavonoids as well as their glycosides can be readily extracted by water,
their non-polar derivatives may be present in the oil components of the plant.
4



























































Goyaglycoside-e Fruits Cytotoxic, Anti-obesity,
Antidiabetic
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Kuguacin B Roots Anticancer, Antidiabetic
Kuguacin C &D Roots Anti-HIV-1,
Antidiabetic













































































Charantoside I Fruits Hypoglycemic,
Anti-obesity
Charantoside II Fruits Hypoglycemic,
Anti-obesity
Charantoside III Fruits Hypoglycemic,
Anti-obesity
Charantoside IV Fruits Hypoglycemic,
Anti-obesity










Goyasaponin I Fruits Hypoglycemic,
Anti-obesity
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Goyasaponin II Fruits Hypoglycemic,
Anti-obesity
Goyasaponin III Fruits Hypoglycemic,
Anti-obesity
















Pharmacological effects of cucurbitane type of triterpenoids of Momordica charantia.
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2.2.3 Other components
Other than the bioactive compounds, unsaturated fatty acids, alkaloids, amino
acids minerals and vitamins are also present in bitter melon. The extracts of bitter
melon shows nine kinds of unsaturated fatty. It has also been demonstrated that 12,
13 and 12 carbon fatty acids are found in young, mature, and senescent leaves of
M. charantia L. representing 87.3%, 95.25%, and 83.11% of the total fatty acids
respectively. The contents of total amino acids and the free amino acids of M.
charantia L. were 11.99% and 2.36% as determined by acid hydrolysis and amino
acid analysis. In addition, bitter melon is a natural source of vitamins; ascorbic acid
was detected in the range of 440–780 mg in the fruit fraction. Vicine is an alkaloidal
agent that has been isolated from the seeds of bitter melon, which is responsible for
hypoglycaemic activity [20].
3. Antiobesity and lipid lowering effects
The various experimental studies reported decrease in serum TC, TG and LDL-C
concentrations and an increase in serum high density lipoprotein-cholesterol (HDL-C)
for bitter melon by different authors. The action of bitter melon in lowering fat has
been supported by plentiful studies, its effect on the level of serum FFAs have been
contradictory with some authors showing reduction, some shown same level, and
others reported an increased levels. For example, the serum FFAs concentration
increased in obese rats treated with bitter melon shown by Chen et al. [21]. An
increased level of TG and LDL-C in the serum that may arises due to either
overproduction by the liver or defective removal from the circulation or the overall
dyslipidaemia in diabetes. It is not clear why bitter melon increase the serum level of
FFAs. It may facilitate fat mobilization due to the suppression of lipogenesis or lipid
deposition. While other revealedM. charantia L. could lower the serum and liver TG
levels [22].
The findings of experimental research conclude that,M. charantia L. may reduce
the fasting insulin, TG, cholesterol and epididymal fat, which were increased by
HFD. The dwindling of insulin resistance, improves glucose tolerance, and increases
insulin signaling under HFD-induced insulin-resistance and elevated serum lipids
may also shown by bitter melon. The administration of an aqueous extract of unripe
fruits of bitter melon improved glucose and insulin tolerance together with inhibi-
tion of plasma apoB-100 and apoB-48. The animal study had shown that, the
evidence of a potent inhibitor of apoB secretion and TG synthesis as well as the
plasma lipid and VLDL effects of bitter melon juice [23]. Overall the studies on the
fruits, seeds, and aerial parts of M. charantia Linn have been shown to reduce
adiposity, lower serum insulin and normalize glucose tolerance in rats fed with a
HFD. The body weight and visceral fat mass of bitter melon treated obese rats were
shown to be lowered [24].
While further study revealed that, bitter melon supplementation into HFD
notably suppressed the levels of fatty acid synthase (FAS), acetyl-CoA carboxylase-
1 (ACC-1), lipoprotein lipase (LPL) and adipocyte fatty acid binding protein [25].
Water extract of M. charantia L. fruits at a dose 1 g/Kg body weight revealed to be
effectual in improving the obesity-induced hyperglycaemia and hyperleptinemia
[26]. This in progression propose that bitter melon can reduce insulin resistance,
visceral fat accumulation and adipocyte hypertrophy probably by down-regulating
the expression of key lipogenic genes or proteins in adipose tissues. Aqueous fruit
extract of M. charantia L. significantly reduce the level of serum TG, TC, LDL and
VLDL at a dose of 350 mg/Kg body weight in experimental rats [27]. Numerous
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animal studies have been designated the efficacy of bitter melon in the amelioration
of weight gain and regulation of lipid metabolism [28].
The methanolic extract of fruit of bitter melon showed antidiabetic and
antihyperlipidemic action during different seasons of the year, this suggests that
antidiabetic and hypolipidemic activity ofM. charantia L. may fluctuate on quantity
and quality of active constituents during different seasons of the year and reach the
peak during spring [29]. The bitter melon seed oil had shown significantly
decreased in body-weight, Lee’s index, fat index and adipose size in the HFD mice.
Meanwhile, the serum FFAs levels returned to normal at the dosage of 10 g/kg [30].
Momordica charantia L. extracts have anti-obesity effects and the ability to modu-
late lipid prolife of mice fed a HFD by suppressing body weight gain, visceral tissue
weight, plasma and hepatic lipid concentrations, and lipid peroxidation along with
increasing lipid metabolism. The plasma TG, TC, and LDL-C levels along with
hepatic TG and TC concentrations considerably lowered in mice fed a HFD by
Momordica charantia L. extracts. Also elevated plasma HDL-C levels and fecal TG
concentration shown in animals treated with the extracts. The extracts comprise
anti-obesity effects in mice fed a HFD by inhibiting lipid peroxidation whereas
increasing lipid metabolism [31]. Bitter melon extract showed useful benefit on
body weight gain and fat deposition.
Moreover, bitter melon reduced the lipid accumulation during differentiation
from a pre-adipocyte to adipocyte and down-regulated PPAR [32]. PPAR is
considered the master regulator of adipogenesis during differentiation of
pre-adipocyte to adipocyte [33]. Bitter melon juice inhibited adipocyte
differentiation by reducing PPAR, SREBP, and perilipin mRNA gene expression
and by increasing lipolysis in primary human adipocyte [34]. Several transcriptional
regulatory factors like AMPK, PPAR, and PGC-1 regulate the mitochondrial biogen-
esis, which would be a possible way of increasing lipid metabolism and utilization in
energy demanding cells and tissues [35]. PGC-1 stimulates mitochondrial biogenesis
and respiration in multiple cell types and modulates biological programs normally
associated with increased oxidative metabolism. Also decreased plasma level of TGs,
cholesterol, and FFA in plasma of rats fed a HF diet revealed by bitter melon
supplementation due to up regulation and activation of PGC-1 [36].
Bitter melon affects on various body organs to treat obesity and diabetes as [37]:
1.Liver
• Increased β-oxidation
• Increased PPAR-α and PPAR-gamma expression
• Increased expression of the transcription coactivator PGC-1α
• Decreased fatty acid synthesis
• Decreased fat
2.Pancreas
• Increased insulin secretion
• Prevents cell damage
• Increased PPAR-α and PPAR- gamma expression in skeletal muscle
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3.Fat cells
• Inhibited adipocyte hypertrophy
• Inhibited adipocyte differentiation
• Increased PPAR-gamma expression
• Increased expression of the transcription co-activator PGC-1α
• Decreased visceral fat mass
AMPK synchronized PPAR and PGC-1 activation encouraged most of the tran-
scriptional signal to augment fatty acid oxidation and mitochondrial function [38].
Recent investigation also reported that increased hepatic AMPK p, AMPK, AMPK-
2, and Sirt1 content in HF diet fed mice with supplementation of 1.2% bitter melon
extract [39]. LXRs were first recognized as orphan members of the nuclear receptor
plays an important role in lipid and cholesterol metabolism and oxidized derivatives
of cholesterol act as ligands for the LXRs. A high cholesterol diet fed mice develop
enlarged fatty livers, degeneration of liver cells, high cholesterol levels in liver, and
impaired liver function by LXR knockout [40]. The M. charantia L. extract supple-
mentation decreased hepatic LXR which was responsible for decreased serum TC
and LDL-C, HDL-C in high cholesterol diet Wistar rats [41]. Bitter melon extract
was a potent inhibitor of lipogenesis and stimulator of lipolysis in 3 T3-L1
pre-adipocyte shown by researcher [42].
4. Toxic effects
The severe adverse reactions were not reported during the short term studies
while extensive data on the potential toxic effect of bitter melon are not available.
Bitter melon fruits are edible and assumed to be well tolerated, at the same time
toxicological evidences were reported to discover its therapeutic potential for
diabetes. The two cases of acute intoxication reported after taking bitter melon tea
[43]. The fruit and seeds demonstrated greater toxicity than the leaf or aerial parts
of the plant. Abdominal pain as a side effect has also been reported in some studies
[44]. The antifertility and abortifacient effects of the M. charantia L. reported in
animals also value advance investigation. An acute disease favism characterized by
hemolytic anemia, in individuals with a hereditary loss of the enzyme glucose-6-
phosphatase has been shown by vicine found in fava bean. Consequently, the
presence of vicine in bitter melon seeds was also suggested to put patients with
glucose-6-phosphatase deficiency at risk [45]. Although there have been no reports
on favism induced by bitter melon, individuals susceptible to the disease should
avoid eating the fruit.
Several studies have been directed to reduce the bitterness of M. charantia L.
preparations attributes to the triterpene compounds and increasing tolerability
by the general public through various formulation approaches. Some recent
studies used β-cyclodextrin at 0.25–2% concentrations to improve sensory quality,
total phenolic content, antioxidant activity and antidiabetic potential of M.
charantia L. juice [46]. Various encapsulation methods of bitter melon extracts
along with optimized spray-drying techniques were also scrutinized to obtain
the powder [47].
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5. Conclusion
M. charantia L. has been broadly studied globally for its medicinal properties
and to treat a number of diseases like diabetes, dyslipidaemia, obesity, and certain
cancers. The extracts of fruits and different compounds seem to exert their
beneficial effects via several mechanisms like PPARs, LXRs and SREBPs mediated
fat metabolism in various tissues, reduces visceral fat accumulation and adipose
hypertrophy. Isolated compounds from this plant like cucurbitane type of
terpenoids, flavonoids and phenolic acids possesses antiobesity potential.
These mechanisms will be directly related to controlling and treating diabetes
mellitus, dyslipidaemia, obesity and related cardiovascular complications.
Thus, further studies are required to conduct more double blind randomized trials
with bitter melon extracts in obese population. In this chapter, we summarized
phytoconstituents of bitter melon and its antiobesity potential. This compilation of
phytochemicals and antiobesity activity of Momordica charantia L. will help the
researchers in designing new untried strategies.
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